Anti-O2 antibodies and uses thereof

US12312397B2 · kind B2 · utility

Assignees

• MedImmune Limited · US
• Humabs BioMed SA · CH

Inventors

• Qun Wang · Gaithersburg, US
• Meghan Pennini · Gaithersburg, US
• Xiaodong Xiao · Gaithersburg, US
• Davide Corti · Bellinzona, CH
• Elisabetta CAMERONI · Bellinzona, CH
• Martina Beltramello · Bellinzona, CH
• Gilad KAPLAN · Gaithersburg, US
• Anna DeMarco · Bellinzona, CH
• Charles K. Stover · Gaithersburg, US

Key dates

• Filing date: Aug 11, 2022
• Grant date: May 27, 2025
• Expiry date: Feb 18, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae 02 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiellapneumoniae) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae 02 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.